Celebrated equity manager underperforms after biotech dive
Fundamental Invest has been generating lower returns than its Danish peers over the past few years. According to Director Michael Voss, this is due to the US downturn for biotech assets. The portfolio has now been trimmed.
Ten years ago, Fundamental Invest was one of the Danish equity-focused funds with the highest returns, but when zooming in on the past five years, the picture is very different.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
